MilliporeSigma is launching its newest high-sensitivity detection platform, the SMCxPRO™ immunoassay system, at Neuroscience 2017, the annual meeting of the Society for Neuroscience, November 11 to 15 in Washington, D.C.
The SMCxPRO™ platform is a next-generation high-sensitivity protein detection technology, offering high speed, high sensitivity for single molecule detection and meets research demands for biomarker and novel target discovery and detection. The SMCxPRO™ technology is designed to fit seamlessly into customer workflow and detect low-abundant proteins at the femtogram/mL level.
The SMCxPRO™ technology holds immense promise where scientists often use microliters of blood plasma or cerebrospinal fluid for analysis. This makes it a key player in biomarker discovery and validation; that can serve translational research in cancer, neurological disorders and other areas.
MilliporeSigma is also launching a new MILLIPLEX® MAP Mouse Amyloid Beta Panel at Neuroscience 2017. The panel enables simultaneous measurement of amyloid beta 1-40 (Aβ40) and amyloid beta 1-42 (Aβ42), saving time and precious samples so you can further your disease progression studies for Alzheimer’s disease.
In addition, MilliporeSigma R&D scientist, Anthony Saporita, will present his poster Multiplex immunoassay detection of Alzheimer’s disease biomarkers in cerebrospinal fluid, plasma, and serum - Session 128.28/P7 – Sunday, November 12, 11:00 – 12:00 p.m., Halls A-C.
At the show, MilliporeSigma will also showcase a platform standardizing computer-controlled microfluidic live-cell imaging and significantly improved classic workflow tools like the cell counter, sterile media filters, and Western blotting membranes that are ingeniously redesigned based on decades of user experience.
Visit MilliporeSigma at booth 1723 at Neuroscience 2017 or learn more here
Visit the event page to find out more about Neuroscience 2017.